Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonic ALA: SDT for Glioblastoma
NCT04845919Phase 2Completed
- Sponsor
- Carlo Besta Neurological Institute
- Start
- Feb 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 5-aminolevulinic acid in glioblastoma multiforme (GBM), sponsored by Carlo Besta Neurological Institute. Started Feb 2023; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT04845919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04845919.